Board of Directors

Martin-Mellish

Martin Mellish

Independent Non-Executive Chairman

Martin Mellish has served as founding director of Aspen Advisory Services Ltd., since 1994. Aspen is a London-based private office overseeing investments in North America, Europe, and Asia. Mr. Mellish serves as non-executive director of Nucana Ltd (NASD: NCNA; member, Audit Committee) a clinical-stage biopharmaceutical company focused on improved chemotherapy agents, and Levitronix Technologies Inc. (Chair, Audit Committee) a technology company handling high-purity fluids for the semiconductor and life science industries, among other non-executive directorships. He is a member of the International Advisory Council of the Massachusetts General Hospital (MGH), Boston.

He holds an M.Sc. from the Master of Health Care Delivery Science program at Dartmouth; an SM (Management) from the Massachusetts Institute of Technology and an M.Sc. (Accounting) from Northeastern University.

Wensheng-Fan

Wensheng Fan

Chief Executive Officer

Wensheng Fan is a Co-Founder and the first employee of Spectral MD. Over the past 11 years he has served as CTO and COO, before becoming the CEO of Spectral MD. He is an executive, entrepreneur, and innovator with over 20 years of experience in natural speech recognition and imaging systems. Mr. Fan held various leadership roles in strategy, engineering, and operations with Sensata Technologies and Philips. He also has a long history of experience in business development and cross-functional team leadership, being a founder and/or early core member of multiple successful start-up companies. Under his leadership, Spectral MD’s DeepView® was granted FDA Breakthrough Device designation and is well on its way to disrupting the field of healthcare and medical technology.

Mr. Fan received his B.S.E.E. degree from Tsinghua University in Beijing, China and M.S.E.E. degree from Northeastern University in Boston.

Erich-Spangenberg

Erich Spangenberg

Non-Executive Director

Erich Spangenberg is a serial entrepreneur and industry luminary in the patent business. Mr. Spangenberg is the Chief Executive Officer and founder of Ipwe, a company which uses blockchain and artificial intelligence to create the intellectual property asset class. Mr. Spangenberg founded nXn Partners, a company that is focused on predictive analytics. He was also the founder and Chief Executive Officer of IPNav, a pioneer and leader in patent monetisation, and a company that generated over half a billion dollars in licensing, settlement, or enforcement revenues for its clients. 

Mr. Spangenberg is a former investment banker (having held positions at Donaldson, Lufkin, and Jenrette) and corporate lawyer (working for Jones Day). From investment banking he joined the corporate world, where he was the president of Smartalk Teleservices and Acclaim Ventures Group. 

Mr. Spangenberg was a Periclean Scholar at Skidmore College, a Distinguished Graduate in his Master’s degree program at The London School of Economics, and was on Law Review at Case Western Reserve University, where he earned his JD.

Richard-Cotton

Richard Cotton

Independent Non-Executive Director

Richard Cotton has a wealth of experience in senior financial roles in life sciences and other sectors, including broadcast and photographic, automotive, filtration and metals. His experience covers all financial management and value creation activities from R&D, to manufacturing and commercial in international organisations. He has significant experience in the development and successful execution of strategy, corporate finance and M&A, capital markets and governance.

Mr. Cotton was Chief Financial Officer of FTSE250 animal health company Dechra Pharmaceuticals plc, and prior to that Chief Financial Officer of medical device and drug formulation business Consort Medical plc. He was also Finance Director of Vitec Group plc, Group Finance Director at Wagon plc and Group Finance Director of McLeod Russel plc. Prior to this he held senior finance roles in Alcoa Inc. 

Fellow of the Chartered Institute of Management Accountants, Mr Cotton holds a BA (Hons) in Business Studies from Kingston University.

Cynthia-Cai

Cynthia Cai

Independent Non-Executive Director

Dr. Cynthia Cai is an executive and investor with over twenty-five years of experience in the healthcare and life science industry. Extensive experience in equity investment, board membership, marketing, and business development.  In-depth understanding of global biotech and life science business, widely recognized as having a unique ability to bridge collaboration between scientists and businesses, between the eastern and western worlds.

Dr. Cai is the founder and president of Tharton Consulting, which provides investment and management consulting services. She is also a venture partner of Viva BioInnovator, an equity investor in biotech innovation with novel solutions to cross multiple therapeutic areas. Before that, she served as senior advisor to Northern Light Venture Capital, led its healthcare investment effort in the United States. Previously Dr. Cai had progressive leadership roles with Agilent Technologies, as global associate vice president of marketing, she was responsible for its billion-dollar Chromatography, Automation, and Mass Spec. business.

Dr. Cai serves on the board of directors for Spectral MD (London: SMD), Arthrosi Therapeutics, F5 Therapeutics, AceLink Therapeutics, Exarta Therapeutics, and Amberstone Biosciences. She is also a member of the board for the Science History Institute in Philadelphia.

Dr. Cai earned a B.A. and M. Eng. from Tsinghua University in Beijing, received her Ph.D. in Chemistry from the University of Massachusetts, and an MBA from The Wharton Business School of the University of Pennsylvania.

Gerald-Beaney

Gerry Beaney

Independent Non-Executive Director

Gerry Beaney is currently a consultant to growth companies seeking strategic advice or funding for expansion. He has carried out senior executive roles in the corporate finance sector for over 25 years. During 2018, he was the Chief Executive Officer of Northland Capital Partners Limited, an institutional stockbroker based in London, and prior to this acted as Northland’s Head of Corporate Finance between 2014 and 2018. From 1997 to 2013, Mr Beaney was a Partner and Head of Capital Markets at Grant Thornton UK LLP which grew to become the largest independent nominated adviser to AIM companies under his leadership.

Prior to 1997, Mr Beaney held various roles with Grant Thornton in the UK and New York City. He is a member of the Institute of Chartered Accountants of Scotland, and was a member of the American Institute of Certified Public Accountants between 1991 and 2016. He holds a Bachelor of Accountancy Degree from the University of Glasgow.